RE:They could be the ones shorting the stock... Donkeyfeathers .... I agree having Witoski is probably the best thing Sva has going for it. He is highly credible and reputable. The study is air tight so the results will be in no question .
The only cards Sernova holds are the clinical results from the pouch trial. Sernova has no control over how to encourage a pharma into a collaboration. The clinical results when fully released will be the catalyst. If Witoski shows that patients are insulin independent or require little to no insulin at all , that will be disruptive . We don't know after islets or how many islet transplants it takes to get therapeutic c peptide production. The study will eventually reveal everything in time.
Pharma will take this for nothing if they can and they can wait it out . Finances are tight. Give. Toleikis another month . I am not thtrilled with the waste of $1.2 million on Ir past years, lack of news flow or credibility from management... but we have a clinical trial that is showing positive results . We have an immunotherapy technology that could potentially remive need of immunosuppresion.
Lots to agree with all on this blog .Bioteck makes valid points , so does Donkeyfeathers. Is the glass half full or half empty ? All I know is that share price needs to go up to cash in the warrants so there is not another financing . How that happens ? I don't care from updated clinical results or collaboration. Something will give . Management is on notice .
Elgin